Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CDK4/6 Inhibitor SHR6390

Known as: SHR6390 
A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor SHR6390 selectively inhibits… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
1095Background: SHR6390 is a novel inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6). This study was conducted to evaluate the… Expand
2019
2019
Inhibition of the cyclin‐dependent kinase (CDK) 4/6‐retinoblastoma (RB) pathway is an effective therapeutic strategy against… Expand
2019
2019
Abstract Background The aim of the present study was to explore the mechanism underlying the poor efficacy of pyrotinib, propose… Expand
2017
2017
BackgroundCell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Highly Cited
2007
Highly Cited
2007
In adult vertebrates, most cells are not in the cell cycle at any one time. Physiological nonproliferation states encompass… Expand
  • figure 1
  • table I
  • figure 3
  • figure 2
  • figure 4
Highly Cited
2001
Highly Cited
2001
We have investigated the regulation of cell-cycle entry in C. elegans, taking advantage of its largely invariant and completely… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2000
2000
The retinoblastoma family proteins pRB, p107, and p130 are phosphorylated and released from E2Fs in the late G1 phase of the cell… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 6
  • figure 5